Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration

• Main Authors: Loh, A.H, Brennan, R.C, Lang, W.H, Hickey, R.J, Malkas, L.H, Sandoval, J.A
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Review
• Published: 2020
• Subjects: 2 morpholino 8 phenylchromone; 8 [4 (1 aminocyclobutyl) phenyl] 9 phenyl 1, 2, 4 triazolo [3, 4 f] [1, 6] naphthyridin 3 (2h) one; 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one; alendronic acid; buparlisib; cixutumumab; cyclophosphamide; dactolisib; dalotuzumab; doxorubicin; enzastaurin; etoposide; everolimus; irinotecan; lomustine; mammalian target of rapamycin; perifosine; phosphatidylinositol 3 kinase; phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase; protein kinase B; protein tyrosine kinase; rapamycin; ridaforolimus; temozolomide; temsirolimus; topotecan; transcription factor FKHR; transcription factor FOXO; unclassified drug; unindexed drug; vinblastine; wortmannin; apoptosis; cancer inhibition; cancer recurrence; cancer survival; cell proliferation; child; childhood cancer; drug dose escalation; drug efficacy; drug tolerability; enzyme inhibition; Ewing sarcoma; febrile neutropenia; gene mutation; hematologic disease; human; mucosa inflammation; neuroblastoma; nonhuman; osteosarcoma; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); protein expression; randomized controlled trial (topic); review; rhabdomyosarcoma; signal transduction; single drug dose; solid tumor; thrombocytopenia
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183186
• Institution: National University of Singapore

10.3389/fonc.2013.00093